IPM Take
LITT is a classic precision-implementation story. The tool may reduce invasiveness, shorten hospital stay and help selected patients who are not ideal candidates for open surgery. But it depends on imaging, neurosurgical expertise, patient selection, equipment, reimbursement and post-procedure follow-up. A minimally invasive treatment can still create a highly exclusive access pathway.
Executive Summary
A large prospective multicenter analysis from the LAANTERN registry, reported in Journal of Clinical Oncology and highlighted by ASCO Post on 28 August, evaluated laser interstitial thermal therapy in 787 patients treated at 25 U.S. centres between 2015 and 2023. The cohort included 445 patients with primary brain tumours and 342 with metastatic lesions. Median hospital stay was 32.4 hours, and 62.6% of patients avoided ICU admission. Among newly diagnosed glioblastoma patients, achieving at least 91% ablation was associated with longer median progression-free survival and overall survival than lower ablation extent. Overall adverse-event rate was 12.8%, with severe or irreversible adverse events in 2.3% and two procedure-related deaths.
Why it matters
- Patients / advocates: A less invasive option may matter for patients who cannot tolerate or access conventional surgery.
- Clinicians: Extent of ablation and lesion size appear central to patient selection and outcome.
- Hospitals / providers: LITT requires specialist neurosurgical teams, MRI-guided workflows, equipment and perioperative governance.
- Payers / HTA bodies: Value assessment must consider length of stay, complications, selection criteria and real-world access.
A shorter hospital stay is not a small thing when the disease is in the brain.
The LAANTERN study gives LITT its largest prospective evidence base to date. The dataset includes 787 patients treated across 25 U.S. centres, covering primary brain tumours, metastatic brain lesions and radiation necrosis. Median hospital stay was just over a day. Most patients avoided ICU admission. For selected patients, that is not only a technical achievement. It is a different experience of care.
But the key word is selected.
LITT is not a universal replacement for open neurosurgery. The evidence suggests outcomes depend heavily on extent of ablation, tumour type and lesion size. In newly diagnosed glioblastoma, patients who achieved at least 91% ablation had markedly better outcomes than those with lower ablation extent. In recurrent metastatic tumours, complete ablation was also associated with longer survival.
That makes implementation complicated.
A treatment can be minimally invasive and still operationally demanding. LITT needs equipment, imaging workflows, trained neurosurgeons, patient selection, anaesthesia, emergency pathways and follow-up. It also requires honesty about risk: the study reported adverse events, severe or irreversible events, and two procedure-related deaths.
This is where access policy matters. If LITT becomes available only in a handful of elite centres, then its promise will be real but narrow. Patients with brain metastases or glioblastoma do not need another technology that exists in principle but is unreachable in practice.
The evidence is moving. The delivery model must move with it.
